These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37116911)

  • 1. Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors.
    Lindeman SD; Mukkamala R; Horner A; Tudi P; Booth OC; Huff R; Hinsey J; Hovstadius A; Martone P; Zhang F; Srinivasarao M; Cox A; Low PS
    J Nucl Med; 2023 May; 64(5):759-766. PubMed ID: 37116911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios.
    Mukkamala R; Carlson DJ; Miller NK; Lindeman SD; Bowen ER; Tudi P; Schleinkofer T; Booth OC; Cox A; Srinivasarao M; Low PS
    J Nucl Med; 2024 Jun; ():. PubMed ID: 38871387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
    J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
    Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
    [No Abstract]   [Full Text] [Related]  

  • 7. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model.
    Lindeman SD; Booth OC; Tudi P; Schleinkofer TC; Moss JN; Kearney NB; Mukkamala R; Thompson LK; Modany MA; Srinivasarao M; Low PS
    J Med Chem; 2024 Jul; 67(14):11827-11840. PubMed ID: 39013156
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
    Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
    Millul J; Koepke L; Haridas GR; Sparrer KMJ; Mansi R; Fani M
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3050-3061. PubMed ID: 37261473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
    Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
    Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study.
    Huang W; Pang Y; Liu Q; Liang C; An S; Wu Q; Zhang Y; Huang G; Chen H; Liu J; Wei W
    Research (Wash D C); 2023; 6():0282. PubMed ID: 38706713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.
    Galbiati A; Zana A; Bocci M; Millul J; Elsayed A; Mock J; Neri D; Cazzamalli S
    J Nucl Med; 2022 Dec; 63(12):1852-1858. PubMed ID: 35589404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
    Zboralski D; Hoehne A; Bredenbeck A; Schumann A; Nguyen M; Schneider E; Ungewiss J; Paschke M; Haase C; von Hacht JL; Kwan T; Lin KK; Lenore J; Harding TC; Xiao J; Simmons AD; Mohan AM; Beindorff N; Reineke U; Smerling C; Osterkamp F
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3651-3667. PubMed ID: 35608703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents.
    Roy J; Hettiarachchi SU; Kaake M; Mukkamala R; Low PS
    Theranostics; 2020; 10(13):5778-5789. PubMed ID: 32483418
    [No Abstract]   [Full Text] [Related]  

  • 18. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.
    Dekempeneer Y; Massa S; Santens F; Navarro L; Berdal M; Lucero MM; Pombo Antunes AR; Lahoutte T; Van Ginderachter JA; Devoogdt N; D'Huyvetter M
    J Nucl Med; 2023 Dec; 64(12):1941-1948. PubMed ID: 38040444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
    Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
    Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.